Nektar Therapeutics Shares Surge on Eczema Drug Success
Nektar Therapeutics' stock surged over 90% after successful midstage trial results for its eczema drug rezpegaldesleukin, which showed significant symptom improvement and demonstrated a new biological approach to treating inflammatory and autoimmune skin conditions.